Correction: Lack of ANKMY2 suppresses kidney cystogenesis in embryonic- and adult-onset polycystic kidney disease. [PDF]
PLOS Genetics Staff.
europepmc +1 more source
Feasibility Study of Empagliflozin in Patients with Autosomal Dominant Polycystic Kidney Disease: Design and Baseline Characteristics. [PDF]
Seliger SL +10 more
europepmc +1 more source
Refining Tolvaptan Dosing in Autosomal Dominant Polycystic Kidney Disease. [PDF]
Dahl NK, Torres VE.
europepmc +1 more source
Association of 24-hour urinary parameters with renal function and other comorbidities in autosomal dominant polycystic kidney disease. [PDF]
Aykut H, Alışır Ecder S, Ecder T.
europepmc +1 more source
Tolvaptan pharmacokinetics and pharmacodynamics in adolescents with autosomal dominant polycystic kidney disease. [PDF]
Shoaf SE, Sikes K.
europepmc +1 more source
Ultrasound Localization Microscopy to Assess the Intrarenal Microvasculature in Autosomal Dominant Polycystic Kidney Disease. [PDF]
Huang C +13 more
europepmc +1 more source
A Review of the Management of Nephrolithiasis in Autosomal Dominant Polycystic Kidney Disease. [PDF]
Raveendran R, Murali V, Fernando H.
europepmc +1 more source
Caroli disease associated with autosomal recessive polycystic kidney disease: CT imaging features of a case report. [PDF]
Aien MT, Osmani H, Haqyar MI.
europepmc +1 more source
TLR2 Activation Enhances Inflammatory Signaling and Accelerates Cyst Growth and Renal Fibrosis in Polycystic Kidney Disease Mice. [PDF]
Wei A +10 more
europepmc +1 more source

